GMAB
Genmab ASNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$16.30B
P/E Ratio
20.27
EPS
$1.31
Beta
0.69
52W High
$35.43
52W Low
$19.59
50-Day MA
$27.06
200-Day MA
$28.96
Dividend Yield
—
Profit Margin
21.00%
Forward P/E
15.67
PEG Ratio
1.68
About Genmab AS
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Fundamentals
| Revenue (TTM) | $3.90B |
| Gross Profit (TTM) | $3.64B |
| EBITDA | $1.33B |
| Operating Margin | 25.10% |
| Return on Equity | 15.00% |
| Return on Assets | 8.48% |
| Revenue/Share (TTM) | $6.29 |
| Book Value | $9.26 |
| Price-to-Book | 2.86 |
| Price-to-Sales (TTM) | 4.18 |
| EV/Revenue | 5.04 |
| EV/EBITDA | 15.28 |
| Quarterly Earnings Growth (YoY) | -72.80% |
| Quarterly Revenue Growth (YoY) | 25.30% |
| Shares Outstanding | $613.93M |
| Float | $60.66M |
| % Insiders | 0.00% |
| % Institutions | 12.48% |
Historical Volatility
HV 10-Day
34.81%
HV 20-Day
33.79%
HV 30-Day
31.21%
HV 60-Day
32.06%
HV Rank
36.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($37.55 target)
9
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026